Search results
Results from the WOW.Com Content Network
The typical seroconversion timecourse for hepatitis B. Seroconversion plays a major role in the diagnosis and treatment of hepatitis B infections. [60] As in other viral infections, seropositivity indicates that an individual has a sufficiently high concentration of antibody or antigen in the blood to be detectable by standard techniques.
The structure of hepatitis B virus. Hepatitis B virus is a member of the Hepadnavirus family. [11] The virus particle, called Dane particle [12] (), consists of an outer lipid envelope and an icosahedral nucleocapsid core composed of protein.
Hepatitis B virus replication. The life cycle of hepatitis B virus is complex. Hepatitis B is one of a few known pararetroviruses: non-retroviruses that still use reverse transcription in their replication process. The virus gains entry into the cell by binding to NTCP [51] on the surface and being endocytosed. Because the virus multiplies via ...
Hepatitis D is a defective virus that requires hepatitis B to replicate and is only found with hepatitis B co-infection. [17] In adults, hepatitis B infection is most commonly self-limiting, with less than 5% progressing to chronic state, and 20 to 30% of those chronically infected developing cirrhosis or liver cancer. [30] Infection in infants ...
Viral hepatitis is liver inflammation due to a viral infection. [1] [2] It may present in acute form as a recent infection with relatively rapid onset, or in chronic form, typically progressing from a long-lasting asymptomatic condition up to a decompensated hepatic disease and hepatocellular carcinoma (HCC).
In immunology, passive immunity is the transfer of active humoral immunity of ready-made antibodies.Passive immunity can occur naturally, when maternal antibodies are transferred to the fetus through the placenta, and it can also be induced artificially, when high levels of antibodies specific to a pathogen or toxin (obtained from humans, horses, or other animals) are transferred to non-immune ...
Hepatitis B vaccines are produced with recombinant DNA techniques and contain immunologic adjuvant. [13] They are available both by themselves and in combination with other vaccines. [13] The first hepatitis B vaccine was approved in the United States in 1981. [15] A recombinant version came to market in 1986. [13]
If the person exposed is an HBsAg positive source (a known responder to HBV vaccine) then if exposed to hepatitis B a booster dose should be given. If they are in the process of being vaccinated or are a non-responder they need to have hepatitis B immune globulin (HBIG) and the vaccine. For known non-responders HBIG and the vaccine should be ...